阿卡替尼获批用于治疗套细胞淋巴瘤。
Acalabrutinib Approved for MCL.
出版信息
Cancer Discov. 2018 Jan;8(1):OF6. doi: 10.1158/2159-8290.CD-NB2017-158. Epub 2017 Nov 10.
Abstract
The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.
摘要
美国食品药品监督管理局（FDA）加速批准了第二代布鲁顿酪氨酸激酶（BTK）抑制剂阿卡替尼，由于其选择性增强，与此前市场上唯一的BTK抑制剂伊布替尼相比，阿卡替尼似乎副作用更少。
Zotero 插件